Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans
- PMID: 20576487
- DOI: 10.1016/j.ejpb.2010.05.009
Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans
Abstract
This study coupled results from biorelevant dissolution tests with in silico simulation technology to forecast in vivo oral absorption of micronized and nanosized aprepitant formulations in the pre- and post-prandial states. In vitro dissolution tests of the nanosized aprepitant formulation and micronized drug were performed in biorelevant and compendial media. An in silico physiologically based pharmacokinetic (PBPK) model was developed based on STELLA software using dissolution kinetics, standard gastrointestinal (GI) parameters and post-absorptive disposition parameters. GI parameters (gastric emptying rate and GI fluid volume) were varied according to the dosing conditions. Disposition parameters were estimated by fitting compartmental models to the in vivo oral PK data. Predictions of in vivo performance in each prandial state were evaluated using the AUC and C(max) generated from the simulated PK profiles. To predict oral absorption from the extremely fast dissolving nanosized aprepitant formulation, several variations on a previously published model were evaluated. Although models that assumed that the formulation behaved as an oral solution or that adjusted the dissolution kinetics according to the different numbers of particles per gram between micronized and nanosized aprepitant generated profiles similar to the observed in vivo data in the fed state, simulated profiles for the fasted state showed much faster absorption than that observed in the in vivo data. This appeared to result from the assumption of no absorption restrictions in those models. To better predict in vivo performance in both fasted and fed states, a model that adds permeability restrictions to absorption was applied. This model not only simulated the in vivo profiles for aprepitant well in both prandial states, but also predicted the dependency of the pharmacokinetics on the dose and the particle size of aprepitant. In conclusion, a model based on STELLA software combined with dissolution results in biorelevant media successfully forecasts the in vivo performance of both nanosized and micronized formulations of aprepitant in the fed and fasted states. Although dissolution is the primary limitation to the rate of absorption for micronized aprepitant, some permeability restrictions are revealed for the nanosized formulation. The results also indicate that biorelevant dissolution media have strong advantages over compendial media in forecasting the in vivo behavior of aprepitant.
2010 Elsevier B.V. All rights reserved.
Similar articles
-
Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.Eur J Pharm Biopharm. 2009 Sep;73(1):107-14. doi: 10.1016/j.ejpb.2009.05.009. Epub 2009 May 22. Eur J Pharm Biopharm. 2009. PMID: 19465123 Clinical Trial.
-
Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.Eur J Pharm Biopharm. 2011 Oct;79(2):349-56. doi: 10.1016/j.ejpb.2011.04.005. Epub 2011 Apr 18. Eur J Pharm Biopharm. 2011. PMID: 21527341 Clinical Trial.
-
Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.Eur J Pharm Biopharm. 2011 Feb;77(2):257-64. doi: 10.1016/j.ejpb.2010.10.012. Epub 2010 Nov 11. Eur J Pharm Biopharm. 2011. PMID: 21074611
-
Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.J Pharm Pharmacol. 2013 Jul;65(7):937-52. doi: 10.1111/jphp.12059. Epub 2013 Mar 25. J Pharm Pharmacol. 2013. PMID: 23738721 Review.
-
Prediction of human pharmacokinetics--gastrointestinal absorption.J Pharm Pharmacol. 2007 Jul;59(7):905-16. doi: 10.1211/jpp.59.7.0001. J Pharm Pharmacol. 2007. PMID: 17637184 Review.
Cited by
-
Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®.Molecules. 2015 Jun 19;20(6):11345-56. doi: 10.3390/molecules200611345. Molecules. 2015. PMID: 26102068 Free PMC article.
-
Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds.AAPS J. 2012 Dec;14(4):677-87. doi: 10.1208/s12248-012-9383-0. Epub 2012 Jun 27. AAPS J. 2012. PMID: 22736294 Free PMC article. Review.
-
Development of a new method to assess nanocrystal dissolution based on light scattering.Pharm Res. 2012 Oct;29(10):2887-901. doi: 10.1007/s11095-012-0795-4. Epub 2012 Jun 12. Pharm Res. 2012. PMID: 22688901
-
Preparation and Optimization of Ibrutinib-Loaded Nanoliposomes Using Response Surface Methodology.Polymers (Basel). 2022 Sep 17;14(18):3886. doi: 10.3390/polym14183886. Polymers (Basel). 2022. PMID: 36146030 Free PMC article.
-
Preparation and Characterization of Aprepitant Solid Dispersion with HPMCAS-LF.ACS Omega. 2022 Oct 24;7(44):39907-39912. doi: 10.1021/acsomega.2c04021. eCollection 2022 Nov 8. ACS Omega. 2022. PMID: 36385804 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources